Skip to main content

LCD L39521: Positron Emission Tomography (PET) Scan for Inflammation and Infection

LCD L39521, Positron Emission Tomography (PET) Scan for Inflammation and Infection, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-01-22 and first in force 2023-08-13. The policy text runs 1,069 words, and its billing and coding article A59318 lists 85 ICD-10-CM codes that support medical necessity for 18 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-01-22
Original effective
2023-08-13
Policy text
1,069 words
Covered ICD-10 codes (articles)
85

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39521
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A59318: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59318 (Billing and Coding: Positron Emission Tomography (PET) Scan for Inflammation and Infection) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59318: Billing and Coding: Positron Emission Tomography (PET) Scan for Inflammation and Infection (Billing and Coding, effective 2026-01-22)

Covered ICD-10-CM codes
85
3 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
18
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59318
ICD-10-CMDescription (FY2027)
D86.85Sarcoid myocarditis
M31.4Aortic arch syndrome [Takayasu]
M31.5Giant cell arteritis with polymyalgia rheumatica
M31.6Other giant cell arteritis
M46.40Discitis, unspecified, site unspecified
M46.41Discitis, unspecified, occipito-atlanto-axial region
M46.42Discitis, unspecified, cervical region
M46.43Discitis, unspecified, cervicothoracic region
M46.44Discitis, unspecified, thoracic region
M46.45Discitis, unspecified, thoracolumbar region
M46.46Discitis, unspecified, lumbar region
M46.47Discitis, unspecified, lumbosacral region
M46.48Discitis, unspecified, sacral and sacrococcygeal region
M46.49Discitis, unspecified, multiple sites in spine
M86.311Chronic multifocal osteomyelitis, right shoulder
M86.312Chronic multifocal osteomyelitis, left shoulder
M86.321Chronic multifocal osteomyelitis, right humerus
M86.322Chronic multifocal osteomyelitis, left humerus
M86.331Chronic multifocal osteomyelitis, right radius and ulna
M86.332Chronic multifocal osteomyelitis, left radius and ulna
M86.341Chronic multifocal osteomyelitis, right hand
M86.342Chronic multifocal osteomyelitis, left hand
M86.351Chronic multifocal osteomyelitis, right femur
M86.352Chronic multifocal osteomyelitis, left femur

Procedure codes: 78429, 78432, 78433, 78459, 78608, 78609, 78811, 78812, 78813, 78814, 78815, 78816, A9552 (Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries), A9598 (Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified), A9601 (Flortaucipir f 18 injection, diagnostic, 1 millicurie), G0219 (Pet imaging whole body; melanoma for non-covered indications), G0235 (Pet imaging, any site, not otherwise specified), G0252 (Pet imaging, full and partial-ring pet scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes)).

Coverage indications, limitations and medical necessity

Positron emission tomography (PET) is a non-invasive diagnostic imaging procedure utilized to assess the level of metabolic activity and perfusion of the organ systems. The positron camera (tomograph) produces cross-sectional tomographic images which are obtained from intravenously administered positron emitting radioactive tracer substances (radiopharmaceuticals) such as 2-[F-18] fluoro-d-glucose (FDG).

The noncoverage NCD for PET scan used for inflammation and infection (220.6.16) retired effective January 1 st 2021. 1 This NCD addressed the use of PET scan for non-oncological indications specific to inflammatory or infectious etiologies including fever of unknown origin, several cardiac conditions, osteomyelitis and infected artificial joints.

Definitions

First-line therapy is an agent used in the initial treatment of a condition.

An adverse event is a documented event that contraindicates further use of the medication or side effects that are not likely to be transient and resolve with further treatment or impair functional capacity and/or daily living activities.

Lack of efficacy is the lack of an expected or desired effect related to therapy when the dosage and duration of therapy meet published standards.

Refractory disease is when the patient fails to respond to all first-line therapies that are standard of care for the condition.

Relapse disease is a recurrence of the disease condition that does not respond to first-line treatments and/or standard of care therapies.

Fever of unknown origin defined as fever higher than 38.3 Celsius (101 degrees Fahrenheit) on several occasions, duration of at least three weeks and uncertain diagnosis after evaluation. 2

Fever- temperature of 101 degrees Fahrenheit or 38.3 Celsius

Immunocompromised (defined as neutropenia for at least one week in the three months before the start of the fever, known HIV infection, hypogammaglobulinemia or use of 10 milligrams Prednisone or equivalent for at least two weeks in the three months before the start of the fever) 3

Coverage

A. Fever of Unknown Origin (FUO)

PET Scan will be considered reasonable and medically necessary for patients ≥ 18 years old for FUO when all of the following conditions are met:

• Fever higher than 38.3 Celsius (101 degrees Fahrenheit) 2,4 AND

• Present for ≥ 21 days defined by fever on ≥ 2 occasions with repeating episodes for ≥ 2 weeks prior to study 4,5 AND

• The patient is not immunocompromised 3,4 AND

• Investigation including history, physical, laboratory analysis and standard imaging is non-diagnostic 6 AND

• Patient does not have any conditions that would limit the ability to interpret the PET scan 7

B. Cardiac

PET scan for evaluation of cardiac sources of infection and inflammation is considered reasonable and medically necessary when:

• Clinical exam and laboratory evaluation lead to clinical suspicion of the condition and this is documented in the medical record AND

• Non-specific or inconclusive imaging from echocardiography and/or CT 6 AND

• PET scan is conducted with cardiac preparation protocol 8,9 AND

• Patient does not have any conditions that would limit the ability to interpret the PET scan (such as recent cardiac/vascular surgery) 10 AND

• The patient is being evaluated for one of the following conditions and the specific criteria has been met:

• Infective Endocarditis: the patient has a prosthetic valve

Device Infections (pacemaker, defibrillators, LVAD, metallic implants) suspected.

Cardiac Sarcoidosis:

The patient has risk factor cardiac sarcoidosis (such as systemic sarcoidosis with cardiac findings) OR

A patient 11 OR

idiopathic sustained ventricular tachycardia unexplained by other causes 12 AND/OR

For guiding subsequent treatment of proven cardiac sarcoidosis if PET scan is the primary test used to follow the patient for the cardiac aspect of sarcoidosis/inflammatory cardiomyopathies (additional studies such cardiac MRI, CT or other nuclear imaging studies for the same purpose are non-covered). 13

Infection of cardiovascular implantable electronic devices:

Diagnosis is inconclusive on standard imaging (echo/CT)

Additional diagnostic studies would impact clinical care (such as decision to remove device or support prolonged antibiotic therapy or not)

Vascular graft infection

• Diagnosis is inconclusive with one of CTA or MRA

• Patient does not have any conditions that would limit the ability to interpret the PET scan

• Additional diagnostic studies would impact clinical care

• Aortitis and Systemic Vasculitis

• Diagnosis is inconclusive with one of CTA or MRA

• Patient does not have any conditions that would limit the ability to interpret the PET scan

• Additional diagnostic studies would impact clinical care

C. Osteomyelitis and Spondylodiscitis

PET Scan will be considered reasonable and medically necessary for diagnosis of equivocal cases of suspected osteomyelitis or spondylodiscitis (with abnormal radiographs or CT findings) when all of the following conditions are met:

• MRI cannot be performed or is non-diagnostic or inconclusive AND

• Patient does not have any conditions that would limit the ability to interpret the PET (such as post-operative or post-traumatic, uncontrolled blood sugars) AND

• Not in conjunction with bone scintigraphy, leukocyte scintigraphy, and/or MOAB scintigraphy

Limitations:

1. The need for PET scan and labeled WBC scan as part of diagnostic evaluation is rare. Individual consideration may be given on redetermination (appeal) for payment in rare, unique circumstances if the medical necessity of both studies and clearly documented in the medical record. Frequent reporting of these services together may trigger focused medical review.

2. The need for PET scan and 67Ga SPECT/CT as part of diagnostic evaluation is rare. Individual consideration may be given on redetermination (appeal) for payment in rare, unique circumstances if the medical necessity of both studies and clearly documented in the medical record. Frequent reporting of these services together may trigger focused medical review.

3. The need for PET scan and cardiac MRI as part of diagnostic evaluation is rare. Individual consideration may be given on redetermination (appeal) for payment in rare, unique circumstances if the medical necessity of both studies and clearly documented in the medical record. Frequent reporting of these services together may trigger focused medical review.

4. Endocarditis- PET scan is not reasonable and necessary for use in native value.

5. PET and PET/CT is not a first-line test and reserved for equivocal diagnostic cases. Use as a first-line study is not considered reasonable and necessary.

6. 18F-PET and PET/CT is not well-established to monitoring response to treatment and use outside of diagnosis is not considered reasonable and necessary with the exception cardiac sarcoidosis.

The following is not considered reasonable and medically necessary:

The use of PET scan for inflammation and infection of other conditions not specifically addressed above will be considered investigational.

Summary of evidence (opening)

Throughout the evidence review (18)F-fluorodeoxyglucose positron emission tomography-computed tomography will be referred to as 18F-PET or 18F-PET/CT.

Contractor Advisory Meeting (CAC)

A CAC meeting on “Pet Scans for Inflammation and Infection” was held on 11/09/22 and subject matter experts (SMEs) reviewed pertinent literature and provided input for the development of this policy. The transcripts and recording are available in the CGS Administrators website: https://www.cgsmedicare.com/partb/medicalpolicy/lcd_discussion_recordings.html. Reference to the SME input will be included throughout the policy.

Fever of Unknown Origin (FUO)

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-08-13
Current revision effective
2026-01-22
Last reviewed by the contractor
2026-01-16
MCD version
8

The contractor lists 5 National Coverage Determinations as related: NCD 220.6 Positron Emission Tomography (PET) Scans - RETIRED, NCD 220.6.20 Beta Amyloid Positron Tomography in Dementia and Neurodegenerative Disease (RETIRED), NCD 220.6.17 Positron Emission Tomography (FDG) for Oncologic Conditions, NCD 220.6.8 FDG PET for Myocardial Viability, NCD 220.6.9 FDG PET for Refractory Seizures. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59355 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39521 cover?

Positron emission tomography (PET) is a non-invasive diagnostic imaging procedure utilized to assess the level of metabolic activity and perfusion of the organ systems. The positron camera (tomograph) produces cross-sectional tomographic images which are obtained from intravenously administered positron emitting radioactive tracer substances (radiopharmaceuticals) such as 2-[F-18] fluoro-d-glucose (FDG). The full 1,069-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39521 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39521?

The companion billing and coding article A59318 lists 85 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39521?

A denial under LCD L39521 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59318's 85 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.